How much revenue does Beijing Centergate Technologies (holding) make?

Beijing Centergate Technologies (holding) reported 2.44 billion CNY in revenue for fiscal year 2025, down 3.5% from 2.53 billion CNY in fiscal year 2024. In Q1 2026 revenue was 472.36 million CNY.

What is Beijing Centergate Technologies (holding)'s largest business segment?

Biopharmaceutical, with 1.90 billion CNY or 74% of segment revenue in fiscal year 2024. Next: Commercial Concrete (17%) and Elderly Care and Health (5%).

What companies are similar to Beijing Centergate Technologies (holding)?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ), Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ), Zhuhai Rundu Pharmaceutical Co., Ltd. (002923.SZ), Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ).

Beijing Centergate Technologies (holding) Co., Ltd. (000931.SZ) Stock

About Beijing Centergate Technologies (holding) Co., Ltd.

Beijing Centergate Technologies (holding) Co., Ltd. engages in the production and sale of topical reagents, tablets, injections in China. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Naltrexone Hydrochloride tablets and injections to block the pharmacological effects of exogenous opioids; Acetaminophen and oxycodone tablets and injections for the treatme...

At a glance

Beijing Centergate Technologies (holding) reported revenue of 2.44 billion CNY for fiscal year 2025, down 3.5% from fiscal year 2024, and net income of 47.89 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 472.36 million CNY, down 23.4% from a year before. Its largest business segment, Biopharmaceutical, brought in 74% of segment revenue in fiscal year 2024.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.